Events

GPAI Paris w/ Joanna Shields

Our CEO Joanna Shields, joins international AI experts from civil society, academia, industry and government at the Global Partnership on Artificial Intelligence (GPAI) Summit in Paris.

This important occasion offers GPAI experts and member governments to showcase recent developments from GPAI working groups in order to discuss how their collective efforts can be best harnessed to advance the responsible development and utilization of AI.

Aiming to engage external partnerships as well, the public-facing event will include reporting on ten working group study topics from the 2021 work plan, as well as additional reflection sessions facilitated by France as the host country.

About GPAI

Launched in June 2020, GPAI ("gee-pay") is a multistakeholder initiative bringing together leading experts from science, industry, civil society, international organizations and government that share values to bridge the gap between theory and practice on AI by supporting cutting-edge research and applied activities on AI-related priorities.

GPAI aims to provide a mechanism for sharing multidisciplinary research and identifying key issues among AI practitioners, with the objective of facilitating international collaboration, reducing duplication, acting as a global reference point for specific AI issues, and ultimately promoting trust in and the adoption of trustworthy AI.

Through the collaboration within our working groups, GPAI assesses – on a comprehensive, objective, open, and transparent basis – the scientific, technical, and socio-economic information relevant to understanding AI impacts, encouraging its responsible development and options for adaptation and mitigation of potential challenges.

Watch the public conference live here →
More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021